AEON: 分析师目标 $5 — AI 分析 (4月 2026)

AEON Biopharma, Inc. is a biopharmaceutical company focused on developing botulinum toxins, primarily ABP-450, for debilitating medical conditions like migraines and cervical dystonia. The company, formerly ALPHAEON Corporation, aims to address unmet needs in therapeutic areas with its innovative toxin-based solutions.

Key Facts: Price: $1.00 Analyst Target: $5.20 AI Score: 44/100 Sector: Healthcare

公司概况

概要：

AEON Biopharma is pioneering botulinum toxin therapies with ABP-450, targeting multi-billion dollar markets in migraine, cervical dystonia, and gastroparesis; a high-risk, high-reward play for investors seeking innovative biotechnology exposure and significant upside potential.

AEON是做什么的？

AEON Biopharma, Inc., established in 2012 and headquartered in Newport Beach, California, is a biopharmaceutical company dedicated to the advancement of botulinum toxin therapies for a range of debilitating medical conditions. Originally incorporated as ALPHAEON Corporation, the company rebranded to AEON Biopharma in December 2019, signaling a strategic shift towards focusing on therapeutic applications of botulinum toxins. AEON's primary focus is the development of ABP-450, a 900 kDa botulinum toxin complex, which is being investigated for the treatment of migraine, cervical dystonia, and gastroparesis. These conditions represent significant unmet medical needs and substantial market opportunities. Migraine, affecting millions worldwide, often requires innovative treatment options beyond existing therapies. Cervical dystonia, a painful neurological disorder causing involuntary neck muscle contractions, also presents a challenging therapeutic landscape. Gastroparesis, a condition characterized by delayed stomach emptying, can significantly impact patients' quality of life. AEON Biopharma aims to provide effective and targeted solutions for these conditions through the precise application of botulinum toxin technology. The company's commitment to research and development underscores its mission to improve patient outcomes and establish a leading position in the botulinum toxin therapeutics market.

AEON的投资论点是什么？

Investing in AEON Biopharma presents a high-risk, high-reward opportunity centered on the potential success of ABP-450. The company's focus on botulinum toxin therapies for conditions like migraine, cervical dystonia, and gastroparesis targets markets with significant unmet needs. Positive clinical trial results for ABP-450 could serve as a major catalyst, driving substantial stock appreciation. With a market capitalization of $0.01 billion and a negative P/E ratio of -4110.68, AEON is currently valued as a speculative growth stock. The company's success hinges on navigating the regulatory landscape and demonstrating the efficacy and safety of ABP-450. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. While the path forward involves inherent risks, the potential for significant returns warrants consideration for investors with a high-risk tolerance.

AEON在哪个行业运营？

AEON Biopharma operates within the biotechnology sector, specifically focusing on botulinum toxin therapeutics. The market for botulinum toxin products is substantial, driven by both cosmetic and therapeutic applications. Competitors include companies like ABP, APM, BOLT, CING, and CLNN, which are also developing or marketing botulinum toxin products. The industry is characterized by intense competition, rigorous regulatory requirements, and significant investment in research and development. Market trends include the development of novel formulations, expanded therapeutic indications, and increasing patient awareness. AEON Biopharma aims to differentiate itself through its focus on specific medical conditions and its proprietary ABP-450 formulation.

Healthcare/Biotechnology

Healthcare

AEON有哪些增长机遇？

Expansion into Migraine Treatment: The migraine treatment market is projected to reach billions of dollars, offering a substantial opportunity for AEON Biopharma. ABP-450's potential efficacy in reducing migraine frequency and severity could capture a significant share of this market. Successful clinical trials and regulatory approval are crucial milestones for realizing this growth potential. Timeline: Regulatory approval within the next 3-5 years.
Advancement in Cervical Dystonia Therapy: Cervical dystonia, a debilitating neurological disorder, represents a niche market with limited treatment options. ABP-450's ability to alleviate muscle spasms and pain associated with cervical dystonia could establish AEON Biopharma as a key player in this therapeutic area. Further clinical studies and patient advocacy efforts will be essential for driving adoption. Timeline: Ongoing clinical trials with potential results within 2 years.
Development of Gastroparesis Treatment: Gastroparesis, characterized by delayed stomach emptying, affects a significant patient population. ABP-450's potential to improve gastric motility and reduce symptoms could address a critical unmet need. Clinical trials focused on gastroparesis are necessary to validate its efficacy and safety. Timeline: Clinical trial initiation within the next year.
Strategic Partnerships and Collaborations: Collaborating with established pharmaceutical companies or research institutions could accelerate the development and commercialization of ABP-450. Strategic partnerships can provide access to funding, expertise, and distribution networks, enhancing AEON Biopharma's market reach. Timeline: Ongoing discussions with potential partners.
Expansion of Therapeutic Indications: Beyond migraine, cervical dystonia, and gastroparesis, ABP-450 may have potential applications in other medical conditions. Exploring additional therapeutic indications through preclinical and clinical studies could broaden AEON Biopharma's product pipeline and market opportunities. Timeline: Identification of new indications within the next 2-3 years.

AEON Biopharma is focused on developing ABP-450, a 900 kDa botulinum toxin complex, for the treatment of migraine, cervical dystonia, and gastroparesis.
The company rebranded from ALPHAEON Corporation to AEON Biopharma in December 2019, signaling a strategic shift towards therapeutic applications.
AEON Biopharma's headquarters are located in Newport Beach, California.
The company's market capitalization is $0.01 billion, reflecting its status as a micro-cap biotechnology firm.
AEON Biopharma has a beta of 0.72, indicating lower volatility compared to the overall market.

AEON提供哪些产品和服务？

Develop botulinum toxin therapies for medical conditions.
Focus on ABP-450, a 900 kDa botulinum toxin complex.
Target migraine, cervical dystonia, and gastroparesis.
Conduct clinical trials to evaluate ABP-450's efficacy and safety.
Seek regulatory approval for ABP-450 from health authorities.
Commercialize botulinum toxin products for therapeutic use.

AEON如何赚钱？

Develop and patent botulinum toxin formulations.
Conduct clinical trials to demonstrate efficacy and safety.
Obtain regulatory approvals for commercialization.
Manufacture and market botulinum toxin products.
Generate revenue through product sales and licensing agreements.

Patients suffering from migraine, cervical dystonia, and gastroparesis.
Physicians who prescribe botulinum toxin therapies.
Hospitals and clinics that administer botulinum toxin treatments.
Pharmacies that dispense botulinum toxin products.

Proprietary botulinum toxin formulation (ABP-450).
Intellectual property protection through patents.
Clinical data demonstrating efficacy and safety.
Regulatory exclusivity upon approval.
Established relationships with physicians and healthcare providers.

什么因素可能推动AEON股价上涨？

Upcoming: Completion of Phase II clinical trials for ABP-450 in migraine (2026).
Upcoming: Initiation of Phase II clinical trials for ABP-450 in gastroparesis (2026).
Ongoing: Publication of clinical trial data in peer-reviewed journals.
Ongoing: Potential for strategic partnerships or licensing agreements.

AEON的主要风险是什么？

Potential: Unfavorable clinical trial results for ABP-450.
Potential: Regulatory delays or rejection of ABP-450.
Ongoing: Competition from established pharmaceutical companies with greater resources.
Ongoing: Risk of product liability claims.
Potential: Dilution of existing shareholders through future financing activities.

AEON的核心优势是什么？

Proprietary botulinum toxin formulation (ABP-450).
Focus on specific medical conditions with unmet needs.
Experienced management team.
Potential for significant market share in targeted therapeutic areas.

AEON的劣势是什么？

Limited financial resources.
Dependence on successful clinical trial outcomes.
Regulatory hurdles and approval timelines.
Competition from established pharmaceutical companies.

AEON有哪些机遇？

Expansion into new therapeutic indications.
Strategic partnerships and collaborations.
Increasing awareness of botulinum toxin therapies.
Growing demand for effective treatments for migraine, cervical dystonia, and gastroparesis.

AEON面临哪些威胁？

Unfavorable clinical trial results.
Regulatory setbacks or delays.
Competition from generic botulinum toxin products.
Product liability claims.

AEON的竞争对手是谁？

Abbott Laboratories — Major pharmaceutical company with diverse product portfolio. — (ABP)
Aptorum Group Limited — Developing novel therapeutics for unmet medical needs. — (APM)
Bolt Biotherapeutics, Inc. — Pioneering Immuno-oncology therapeutics. — (BOLT)
Cingulate Inc. — Focusing on ADHD and cognitive disorders. — (CING)
Clene Inc. — Developing bioenergetic nanocatalysis medicines. — (CLNN)

Key Metrics

Price: $1.00 (-1.96%)
Market Cap: $12
Volume: NaN
MoonshotScore: 44/100

Analyst Price Target

Analyst Consensus Target: $5.20
Current Price: $1.00
Implied Upside: +420.0%

常见问题

What does AEON Biopharma, Inc. (AEON) do?

AEON Biopharma, Inc. is a biopharmaceutical company that specializes in the development of botulinum toxin-based therapies. Its primary focus is on ABP-450, a 900 kDa botulinum toxin complex, which is being investigated for the treatment of debilitating medical conditions such as migraine, cervical dystonia, and gastroparesis. The company aims to provide innovative and effective solutions for patients suffering from these conditions by leveraging the therapeutic properties of botulinum toxins. AEON Biopharma is dedicated to advancing its product pipeline through clinical trials and regulatory approvals, with the goal of improving patient outcomes and establishing a leading position in the botulinum toxin therapeutics market.

Is AEON stock a good buy?

Evaluating whether AEON stock is a good buy requires careful consideration of its potential and risks. With a market capitalization of $0.01 billion and a negative P/E ratio, AEON is a speculative investment. The success of ABP-450 in clinical trials and regulatory approvals is critical for its future growth. While the potential upside is significant if ABP-450 proves effective, investors should be aware of the inherent risks associated with biotechnology companies, including clinical trial failures, regulatory setbacks, and competition. A balanced approach involves assessing your risk tolerance and conducting thorough due diligence before investing in AEON stock.

What are the risks of investing in AEON?

Investing in AEON Biopharma carries several risks typical of micro-cap biotechnology companies. A significant risk is the potential for dilution, as the company may need to issue more shares to fund its operations and clinical trials. Another key risk is the possibility of clinical trial failures or regulatory setbacks for ABP-450, which could negatively impact the stock price. Additionally, AEON faces competition from larger, more established pharmaceutical companies with greater resources. The company's financial position and cash burn rate should also be closely monitored, as it may require additional funding in the future. These factors contribute to the overall risk profile of investing in AEON.

What catalysts could move AEON stock?

Several potential catalysts could drive AEON stock higher. Positive results from ongoing and upcoming clinical trials for ABP-450 in migraine, cervical dystonia, and gastroparesis would be significant catalysts. Regulatory milestones, such as the acceptance of a New Drug Application (NDA) or the granting of FDA approval for ABP-450, could also boost investor confidence. Strategic partnerships or licensing agreements with larger pharmaceutical companies could provide financial resources and validation of AEON's technology. Furthermore, positive coverage from analysts or industry publications could increase awareness and demand for AEON stock.

What is AEON stock price target?

As of March 3, 2026, there is no readily available analyst consensus price target for AEON stock, likely due to its micro-cap status and limited analyst coverage. Determining a fair value estimate would require a detailed analysis of AEON's pipeline, clinical trial data, regulatory prospects, and financial projections. Investors should conduct their own due diligence and consider various valuation methods, such as discounted cash flow analysis or peer comparisons, to arrive at a reasonable price target. It's important to note that price targets are inherently subjective and can vary widely depending on the assumptions used.

Is AEON a good investment right now?

Use the AI score and analyst targets on this page to evaluate AEON Biopharma, Inc. (AEON). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for AEON?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates AEON Biopharma, Inc. across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find AEON financial statements?

AEON Biopharma, Inc. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.